Clinical Trial Update: Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning [Phase 2]

View source ↗

Summary

Phase 2 study of alemtuzumab (MabCampath) in hematopoietic transplantation from an unrelated donor with reduced intensity conditioning was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• MabCampath (alemtuzumab)

Snippet

Sponsor: CABYC | Conditions: Graft Versus Host Disease | Phase 2 | Status: TERMINATED